International Stem Cell (ISCO) Cash & Equivalents (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Cash & Equivalents of $993000.0 for Q4 2025, down 19.27% year-over-year from $1.2 million in Q4 2024, and up 2.8% quarter-over-quarter from $966000.0 in Q3 2025.
International Stem Cell (ISCO) Cash & Equivalents (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Cash & Equivalents for 16 consecutive years, with $993000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash & Equivalents fell 19.27% year-over-year to $993000.0; the TTM figure through Dec 2025 stood at $993000.0 (down 19.27% YoY), while the FY2025 annual figure was $993000.0, down 19.27% from the prior year.
- Cash & Equivalents advanced to $993000.0 in Q4 2025 per ISCO's latest filing, from $966000.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $1.6 million in Q4 2023 and bottomed at $171000.0 in Q4 2021.
- Historically, Cash & Equivalents has averaged $955000.0 across 5 years, with a median of $979500.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 333.92% — and 2025, when it slumped 84.65%.
- International Stem Cell's Cash & Equivalents stood at $171000.0 in 2021, then surged by 333.92% to $742000.0 in 2022, then soared by 114.02% to $1.6 million in 2023, then fell by 22.54% to $1.2 million in 2024, then slipped by 19.27% to $993000.0 in 2025.
- Business Quant data shows ISCO's Cash & Equivalents at $993000.0 in Q4 2025, $966000.0 in Q3 2025, and $198000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.09 Mn |
| Dec 31, 2025 | 993,000.00 |
| Sep 30, 2025 | 966,000.00 |
| Jun 30, 2025 | 198,000.00 |
| Mar 31, 2025 | 1.45 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | 943,000.00 |
| Dec 31, 2022 | 742,000.00 |
| Sep 30, 2022 | 666,000.00 |
| Jun 30, 2022 | 586,000.00 |
| Mar 31, 2022 | 398,000.00 |
| Dec 31, 2021 | 171,000.00 |
| Sep 30, 2021 | 505,000.00 |
| Jun 30, 2021 | 750,000.00 |